Home » Wyeth’s Pipeline Hits a Snag
Wyeth’s Pipeline Hits a Snag
The Food and Drug Administration’s rejection of Wyeth’s schizophrenia drug bifeprunox is the latest in a string of disappointments that is sapping the confidence of investors in the big drug company’s long-term growth prospects.
The Wall Street Journal
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May